Please assess the completion status of the following clinical trial:

Trial Title: Alemtuzumab (Campath) to Treat T-Large Granular Lymphocyte Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
* INCLUSION CRITERIA:~Clinical history supportive of the diagnosis of T-LGL leukemia (i.e. a history of cytopenias with peripheral blood morphologic evidence of LGLs)~Immunophenotypic studies of peripheral blood showing an increased population of T-LGLs (suggested by staining with CD3+, CD8+ and CD16+ or CD57+) or gammadelta T cells~Restricted or clonal rearrangement of the T-cell receptor by PCR AND one or more of the following:~Severe neutropenia (less than 500 neutrophils/microliter); OR~Severe thrombocytopenia (less than 20,000 platelets/microliter), or moderate thrombocytopenia (less than 50,000 platelets/microliter) with active bleeding; OR~Symptomatic anemia with a hemoglobin less than 9 g/dL or red blood cell transfusion requirement of greater than 2 units/month for two months prior to initiation of Campath~Ages 18-85 (both inclusive)~EXCLUSION CRITERIA:~A reactive LGL lymphocytosis to a viral infection~Serologic evidence of HIV infection~Infection not adequately responding to appropriate therapy~Previous immunosuppressive therapy with alemtuzumab~History of carcinoma that is not considered cured (excluding non-melanoma skin carcinoma)~Moribund status or concurrent hepatic, renal, cardiac, neurologic, pulmonary, infectious, or metabolic disease of such severity that it would preclude the subject's ability to tolerate protocol therapy or that death within 7-10 days is likely~Current pregnancy or unwilling to take oral contraceptives or refrain from pregnancy if of childbearing potential~Not able to understand the investigational nature of the study or give informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Alemtuzumab in patients with T cell large granular lymphocytic leukemia (T-LGL) (Type: EXPERIMENTAL): Alemtuzumab (Campath) will be administered at 10 mg/dose IV for 10 days as an infusion over 2 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).